Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Identifying a high-risk cellular signature in the multiple myeloma bone marrow microenvironment_1

ABSTRACT: The multiple myeloma (MM) tumor microenvironment is thought to influence patient outcomes. To test this, we computationally enumerated relevant cell populations in 436 newly diagnosed MM patients. Unsupervised clustering identified 5 clusters, with patients in Cluster 5 having significantly worse outcomes: 13 fewer months of progression-free survival (P = 0.002) and 8 fewer months of overall survival (P = 0.040). Cell type analysis showed that patients in Cluster 5 had elevated CD8+ T cell and B cell populations, but low granulocyte levels. A granulocyte signature identified an additional 14% of patients with elevated risk but lacking International Staging System stage III or GEP-70 high- risk status

ORGANISM(S): Homo sapiens

PROVIDER: GSE136324 | GEO | 2019/08/31

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Identifying a high-risk cellular signature in the multiple myeloma bone marrow microenvironment_3

Project description:The multiple myeloma (MM) tumor microenvironment is thought to influence patient outcomes. To test this, we computationally enumerated relevant cell populations in 436 newly diagnosed MM patients. Unsupervised clustering identified 5 clusters, with patients in Cluster 5 having significantly worse outcomes: 13 fewer months of progression-free survival (P = 0.002) and 8 fewer months of overall survival (P = 0.040). Cell type analysis showed that patients in Cluster 5 had elevated CD8+ T cell and B cell populations, but low granulocyte levels. A granulocyte signature identified an additional 14% of patients with elevated risk but lacking International Staging System stage III or GEP-70 high- risk status

2019-08-31 | GSE136398 | GEO

Identifying a high-risk cellular signature in the multiple myeloma bone marrow microenvironment_2

2019-08-31 | GSE136337 | GEO

Overexpression of miR-200c/141 and miR-200b/200a/429 in MDA-MB-436 cells

Project description:We previously showed that overexpression of the miR-200c/141 cluster in the TNBC cell line MDA-MB-231 significantly reduced proliferation and invasion in vitro and tumor growth and metastasis in vivo. To confirm the effects of miR-200s in another TNBC cell line, MDA-MB-436 cells were created to overexpress both the miR-200c/141 cluster and the miR-200b/200a/429 cluster.

2025-08-31 | GSE262478 | GEO

DNA methylation signatures correlate with response to immune checkpoint inhibitors in metastatic melanoma

Project description:DNA methylation profiles were recently proposed to have predictive value in various solid tumors. Therefore, we analyzed DNA methylation profiles of patients with stage IV metastatic melanoma, receiving first-line immune checkpoint inhibitors (ICIs) and correlated those with radiological response (iRECIST). Overall, 81 tissue samples from 71 patients with metastatic melanoma (27 (38.0%) female, 44 (62.0%) male) were investigated; median progression free survival was 8.5 months (0 – 104.1 months) and median overall survival was 30.6 months (0 – 104.1 months), respectively. 29 (40.8%) patients achieved an objective response. DNA methylation analyses revealed signatures correlating with radiological response to ICIs. Based on the 500 mostly differentially methylated genes, three clusters were identified with the majority of responders being in cluster 1 (12/12) and cluster 2 (12/24), and non-responders in cluster 3 (39/45). Our findings indicate that tumor DNA methylation profiling may be used as a predictor for ICI-response in patients with metastatic melanoma.

2024-04-03 | GSE235122 | GEO

Transcription profiling by microarray of High-density neutrophils in multiple myeloma and monoclonal gammopathy patients compared to healthy donors.

Project description:Multiple Myeloma (MM) is a plasma cell malignancy with a well- documented immune dysfunction. We previously showed that granulocyte-myeloid derived suppressor cells (G-MDSC) are increased in MM thus to contribute to refractoriness to lenalidomide. MM-, differently from MGUS, mesenchymal cells lead myeloid precursors to acquire G-MDSC phenotype, suggesting that MM-microenvironment can affect myeloid maturation. Because there is a phenotypic overlapping between G-MDSC and mature high-density neutrophils (HDN), we investigated functionally HDN to gauge their contribution in immune-suppression in patients affected by monoclonal gammopathy of uncertain significance (MGUS) and symptomatic MM.

2020-01-20 | E-MTAB-6105 | biostudies-arrayexpress

Double-deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor

Project description:Cytogenetics abnormalities (CA) are known to be the preponderant prognostic factor in multiple myeloma (MM). Our team has recently developeda prognostic score based on 6 CA, where del(1p32) appears to be the second worst abnormality after del(17p). The aim of this study was to confirm the adverse impact of 1p32 deletion on newly-diagnosed multiple myeloma (NDMM) patients. Among 2551 NDMM patients, 11% were harboring del(1p32). Their overall survival (OS) was half as long as the OS of patients without del(1p32) (49 months vs. 124 months). Likewise, progression-free survival was significantly shorter. More importantly, double-deletion of the 1p32 locus conferred a dramatically poorer prognosis than a monoallelic del(1p32) (OS: 25 months vs. 60 months). As expected, the OS of del(1p32) patients significantly decreased when this abnormality was associated with other high-risk CA (del(17p), t(4;14) or gain(1q)). In the multivariate analysis, del(1p32) appeared as a negative prognostic factor; after adjustment for age and treatment, the risk of progression was 1.3 times higher among patients harboring del(1p32), and the risk of death was 1.9 times higher. At the dawn of risk-adapted treatment strategies, we have confirmed the adverse impact of del(1p32) in MM and the relevance of its assessment at diagnosis.

2022-12-14 | GSE216574 | GEO

Discovery and Development of CD70 As a Cellular Therapy Target in High Risk Multiple Myeloma

Project description:Even in the BCMA CAR-T era, multiple myeloma (MM) patients with high-risk genotypes have the poorest outcomes. We thus leveraged MMRF CoMMpass data to identify potential novel surface immunotherapeutic targets in high-risk MM. As described below, we focused on CD70, an immunotherapeutic target known to be upregulated on many hematologic and solid tumors but minimally expressed on normal tissue. While CD70 was previously explored in MM (McEarchern et al, Clin Cancer Res (2008)), it was not further investigated due to heterogeneous expression in newly diagnosed samples. Here we revisit this target to suggest cellular therapies against CD70 could be highly beneficial in high-risk MM patients, currently the greatest unmet need in the field.

2025-11-27 | PXD048492 | Pride

Identification of a novel NF-kB target gene in human triple-negative breast cancer cells

Project description:Analysis of human triple-negative breast cancer cells (TNBCs) which have high NF-kB activity. Proteins derived from NF-ÎºB target genes might be molecular targets for cancer therapy. Results provide new insights into tumor proliferation mechanisms. Exp. 1: Mock MDA-MB-436 cells vs. MDA-MB-436 cells infected with Adenovirus-IkBaSR; Exp. 2: MDA-MB-436 cells infected with Adenovirus-GFP vs. MDA-MB-436 cells infected with Adenovirus-IkBaSR.

2015-02-20 | E-GEOD-56812 | biostudies-arrayexpress

Reconstruction of microRNA/genes transcriptional regulatory networks of multiple myeloma through in silico integrative genomics analysis [MM, gene]

Project description:The identification of deregulated miRNA in multiple myeloma (MM) has progressively added a further level of complexity to MM biology. In the present study, we take virtue of in silico integrative genomics analysis to generate an unprecedented global view of the transcriptional regulatory networks modulated in MM to define microRNAs impacting in regulatory circuits with potential functional and clinical relevance. miRNA and gene expression profiles in two large representative MM datasets, available from retrospective and prospective clinical trials and encompassing a total of 249 patients at diagnosis, were analyzed by means of two robust computational procedure to identify (i) relevant miRNA/transcription factors/target gene circuits in the disease and (ii) highly modulated miRNA-gene networks in those pathways enriched with miRNA-target gene interactions in specific MM subgroups. The analysis reinforced the pivotal role the miRNA cluster miR-99b/let-7e/miR-125a, specifically deregulated in MM patients with t(4;14) translocation, and disentangled its major relationships with transcriptional relevance. Integrated pathway analyses performed on the expression data of the MM patients stratified according to t(4;14) further allowed to define the pathway composed by the interactions that mainly characterize this MM subset and unravel connected pathways with putative role in the tumor biology.

2016-03-23 | GSE70319 | GEO

Reconstruction of microRNA/genes transcriptional regulatory networks of multiple myeloma through in silico integrative genomics analysis [MM, miRNA]

2015-12-08 | GSE70254 | GEO